$BMY Headlines Coach slides on downgrade; Fuel
Post# of 102729
Posted On: 06/07/2014 11:35:54 AM
$BMY Headlines
Coach slides on downgrade; FuelCell slumps on results 3:43 p.m. June 4, 2014 - Sue Chang
Rising health-care costs are enough to make you sick 6:00 a.m. May 29, 2014 - Al Lewis
Cisco jumps on profit beat; Plug Power gains on upgrade 3:35 p.m. May 15, 2014 - Sue Chang
Pfizer’s AstraZeneca bid is a ‘deal from hell’ 10:18 a.m. May 15, 2014 - Howard Gold
Bristol-Myers slides 4.7%, worst S&P 500 loser 9:33 a.m. May 15, 2014 - Sue Chang
Earnings roundup: Cubist, Merck gain as HCA, Bristol-Myers slide 11:48 a.m. April 29, 2014 - Russ Britt
Value trumps growth as investors pick Exxon over Tesla 10:48 a.m. April 29, 2014 - William L. Watts
Twitter, eBay, Sprint, Herbalife are stocks to watch 5:31 a.m. April 29, 2014 - Sue Chang
Market leaders energy, utilities face earnings gauntlet 11:17 a.m. April 28, 2014 - Wallace Witkowski
The market in a minute: Sell calls and puts 11:11 a.m. April 28, 2014 - The Trading Deck
GlaxoSmithKline exits cancer drugs 8:36 a.m. April 22, 2014 - MarketWatch.com
Merck: Hepatitis C drug has 98% cure rate in trial 11:43 a.m. April 10, 2014 - MarketWatch.com
Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:09 p.m. June 6, 2014 - TheStreet.com
The Case for Health-Care Stocks 3:19 p.m. June 6, 2014 - The Wall Street Journal Interactive Edition
Top Analyst Upgrades and Downgrades: Apple, Lululemon, Microsoft, NBG, Twitter, Whole Foods and More 7:37 a.m. June 5, 2014 - 247WallSt.com
ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy 1:08 p.m. June 4, 2014 - benzinga.com
ASCO Meeting Day 3: Do More Treatments Equal A Longer Life? 12:58 p.m. June 4, 2014 - benzinga.com
Bristol-Myers Squibb (BMY) Hosts Bristol-Myers Squibb Investor Event: ASCO 2014 (Transcript) 4:56 p.m. June 2, 2014 - Seeking Alpha
Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14 3:20 p.m. June 2, 2014 - TheStreet.com
Bristol Defends Data; Roche Shines In Cancer Showdown 1:14 p.m. June 2, 2014 - Investors Business Daily
3 Stocks Pushing The Drugs Industry Downward 1:03 p.m. June 2, 2014 - TheStreet.com
Drug Giants Advance Cancer Treatments 10:30 a.m. June 2, 2014 - FOXBusiness
Immunotherapies dominate the agenda at ASCO 8:01 a.m. June 2, 2014 - Seeking Alpha
Bristol's Immunotherapy Duo Doubles Survival in Melanoma Patients 7:33 a.m. June 2, 2014 - TheStreet.com
S&P 500 Crawls to New High Ahead of ISM Data 7:31 a.m. June 2, 2014 - FOXBusiness
Merck Immunotherapy Posts Striking Results Against Advanced Melanoma 7:31 a.m. June 2, 2014 - TheStreet.com
Stock Futures Tick Up on China Data 7:31 a.m. June 2, 2014 - FOXBusiness
Cancer Drugs Show Promise 7:30 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
Drug Firms Target Smaller Deals 7:21 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
ASCO '14: Sell-Side Buzz Over Big Pharma Immuno-Oncology Pipelines 6:54 a.m. June 2, 2014 - TheStreet.com
Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival 6:38 a.m. June 2, 2014 - benzinga.com
What Merck, Bristol-Myers Squibb And Roche Are Doing To Win The Immuno-Oncology Drugs Market 4:30 p.m. May 30, 2014 - Seeking Alpha
Thought Leader Opinion Indicates That There is Significant Commercial Opportunity in Developing Therapies that Can Improve Overall Survival in First-Line Advanced Ovarian Cancer 1:00 p.m. June 5, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care Conference 12:34 p.m. June 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Syngene International Extend Research Collaboration 7:01 a.m. June 3, 2014 - BusinessWire - BZX
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Premier Biomedical Advances New Cancer Treatment Methodology Protocol 9:01 a.m. May 28, 2014 - ACCESSWIRE
Actavis Confirms Generic Onglyza® Patent Challenge 4:05 p.m. May 27, 2014 - PR Newswire - PRF
Glivec is the Favored First-Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myelogenous Leukemia, According to Surveyed European Hematological Oncologists 11:00 a.m. May 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:00 a.m. May 27, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina 8:30 a.m. May 22, 2014 - PR Newswire - PRF
Basal Cell Carcinoma (Basal Cell Epithelioma) Global Clinical Trials Review, H1, 2014 11:35 a.m. May 21, 2014 - PR Newswire - PRF
Active Stocks Roundup -- Research on Masco Corp., Hecla Mining, Banco Santander, and Bristol-Myers Squibb 11:29 a.m. May 21, 2014 - PR Newswire - PRF
Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent 7:50 a.m. May 19, 2014 - PR Newswire - PRF
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards 2:43 p.m. May 16, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights 8:00 a.m. May 16, 2014 - BusinessWire - BZX
Exosomes Common Link in Cancer Drug Development 2:18 p.m. May 15, 2014 - ACCESSWIRE
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets 3:50 p.m. May 14, 2014 - ACCESSWIRE
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab 8:00 a.m. May 14, 2014 - BusinessWire - BZX
Coach slides on downgrade; FuelCell slumps on results 3:43 p.m. June 4, 2014 - Sue Chang
Rising health-care costs are enough to make you sick 6:00 a.m. May 29, 2014 - Al Lewis
Cisco jumps on profit beat; Plug Power gains on upgrade 3:35 p.m. May 15, 2014 - Sue Chang
Pfizer’s AstraZeneca bid is a ‘deal from hell’ 10:18 a.m. May 15, 2014 - Howard Gold
Bristol-Myers slides 4.7%, worst S&P 500 loser 9:33 a.m. May 15, 2014 - Sue Chang
Earnings roundup: Cubist, Merck gain as HCA, Bristol-Myers slide 11:48 a.m. April 29, 2014 - Russ Britt
Value trumps growth as investors pick Exxon over Tesla 10:48 a.m. April 29, 2014 - William L. Watts
Twitter, eBay, Sprint, Herbalife are stocks to watch 5:31 a.m. April 29, 2014 - Sue Chang
Market leaders energy, utilities face earnings gauntlet 11:17 a.m. April 28, 2014 - Wallace Witkowski
The market in a minute: Sell calls and puts 11:11 a.m. April 28, 2014 - The Trading Deck
GlaxoSmithKline exits cancer drugs 8:36 a.m. April 22, 2014 - MarketWatch.com
Merck: Hepatitis C drug has 98% cure rate in trial 11:43 a.m. April 10, 2014 - MarketWatch.com
Market rookie Five Prime's shares surge on deal with Bristol-Myers 12:01 p.m. March 17, 2014 - Russ Britt
RadioShack sinks; J.C. Penney gains on S&P outlook hike 5:19 p.m. March 4, 2014 - Sue Chang
Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment 5:01 p.m. March 4, 2014 - Russ Britt
Billionaire Stan Druckenmiller's recent moves 12:50 p.m. Feb. 24, 2014 - Insider Monkey
Feds, pharma rivals team up on Alzheimer's 3:32 p.m. Feb. 6, 2014 - Elizabeth O'Brien
Merck hits a new high as analyst sees opening for new cancer drug 12:16 p.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 6:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 4:50 p.m. Jan. 24, 2014 - Sue Chang
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:09 p.m. June 6, 2014 - TheStreet.com
The Case for Health-Care Stocks 3:19 p.m. June 6, 2014 - The Wall Street Journal Interactive Edition
Top Analyst Upgrades and Downgrades: Apple, Lululemon, Microsoft, NBG, Twitter, Whole Foods and More 7:37 a.m. June 5, 2014 - 247WallSt.com
ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy 1:08 p.m. June 4, 2014 - benzinga.com
ASCO Meeting Day 3: Do More Treatments Equal A Longer Life? 12:58 p.m. June 4, 2014 - benzinga.com
Bristol-Myers Squibb (BMY) Hosts Bristol-Myers Squibb Investor Event: ASCO 2014 (Transcript) 4:56 p.m. June 2, 2014 - Seeking Alpha
Incyte's 'IDO' Cancer Immunotherapy Causes Investor Scrum at ASCO '14 3:20 p.m. June 2, 2014 - TheStreet.com
Bristol Defends Data; Roche Shines In Cancer Showdown 1:14 p.m. June 2, 2014 - Investors Business Daily
3 Stocks Pushing The Drugs Industry Downward 1:03 p.m. June 2, 2014 - TheStreet.com
Drug Giants Advance Cancer Treatments 10:30 a.m. June 2, 2014 - FOXBusiness
Immunotherapies dominate the agenda at ASCO 8:01 a.m. June 2, 2014 - Seeking Alpha
Bristol's Immunotherapy Duo Doubles Survival in Melanoma Patients 7:33 a.m. June 2, 2014 - TheStreet.com
S&P 500 Crawls to New High Ahead of ISM Data 7:31 a.m. June 2, 2014 - FOXBusiness
Merck Immunotherapy Posts Striking Results Against Advanced Melanoma 7:31 a.m. June 2, 2014 - TheStreet.com
Stock Futures Tick Up on China Data 7:31 a.m. June 2, 2014 - FOXBusiness
Cancer Drugs Show Promise 7:30 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
Drug Firms Target Smaller Deals 7:21 a.m. June 2, 2014 - The Wall Street Journal Interactive Edition
ASCO '14: Sell-Side Buzz Over Big Pharma Immuno-Oncology Pipelines 6:54 a.m. June 2, 2014 - TheStreet.com
Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival 6:38 a.m. June 2, 2014 - benzinga.com
What Merck, Bristol-Myers Squibb And Roche Are Doing To Win The Immuno-Oncology Drugs Market 4:30 p.m. May 30, 2014 - Seeking Alpha
Thought Leader Opinion Indicates That There is Significant Commercial Opportunity in Developing Therapies that Can Improve Overall Survival in First-Line Advanced Ovarian Cancer 1:00 p.m. June 5, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care Conference 12:34 p.m. June 3, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Syngene International Extend Research Collaboration 7:01 a.m. June 3, 2014 - BusinessWire - BZX
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Premier Biomedical Advances New Cancer Treatment Methodology Protocol 9:01 a.m. May 28, 2014 - ACCESSWIRE
Actavis Confirms Generic Onglyza® Patent Challenge 4:05 p.m. May 27, 2014 - PR Newswire - PRF
Glivec is the Favored First-Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myelogenous Leukemia, According to Surveyed European Hematological Oncologists 11:00 a.m. May 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets 7:01 a.m. May 27, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies 7:00 a.m. May 27, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina 8:30 a.m. May 22, 2014 - PR Newswire - PRF
Basal Cell Carcinoma (Basal Cell Epithelioma) Global Clinical Trials Review, H1, 2014 11:35 a.m. May 21, 2014 - PR Newswire - PRF
Active Stocks Roundup -- Research on Masco Corp., Hecla Mining, Banco Santander, and Bristol-Myers Squibb 11:29 a.m. May 21, 2014 - PR Newswire - PRF
Recognitions, Agreements, Study Results, Data Presentations, and Financial Results - Analyst Notes on Baxter, Incyte, Isis, Celldex Therapeutics, Inc. and Agilent 7:50 a.m. May 19, 2014 - PR Newswire - PRF
TogoRun Named "International Agency Of The Year" At The 2014 PRWeek Global Awards 2:43 p.m. May 16, 2014 - PR Newswire - PRF
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights 8:00 a.m. May 16, 2014 - BusinessWire - BZX
Exosomes Common Link in Cancer Drug Development 2:18 p.m. May 15, 2014 - ACCESSWIRE
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets 3:50 p.m. May 14, 2014 - ACCESSWIRE
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab 8:00 a.m. May 14, 2014 - BusinessWire - BZX
(0)
(0)